<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Give detailed step-by-step instructions for extrac</title>
    <style>
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        .container {
            background-color: white;
            padding: 30px;
            border-radius: 8px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        .content {
            white-space: pre-wrap;
            word-wrap: break-word;
        }
        .metadata {
            display: none;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="content">CN101804096A - Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy - Google Patents Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy Download PDF Info Publication number CN101804096A CN101804096A CN201010107295A CN201010107295A CN101804096A CN 101804096 A CN101804096 A CN 101804096A CN 201010107295 A CN201010107295 A CN 201010107295A CN 201010107295 A CN201010107295 A CN 201010107295A CN 101804096 A CN101804096 A CN 101804096A Authority CN China Prior art keywords purified total alkaloids chinensis vomica total Prior art date 2010-02-08 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Application number CN201010107295A Other languages Chinese ( zh ) Other versions CN101804096B ( en Inventor 蔡宝昌 陈军 陈志鹏 Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Nanjing University of Chinese Medicine Original Assignee Nanjing University of Chinese Medicine Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2010-02-08 Filing date 2010-02-08 Publication date 2010-08-18 2010-02-08 Application filed by Nanjing University of Chinese Medicine filed Critical Nanjing University of Chinese Medicine 2010-02-08 Priority to CN2010101072954A priority Critical patent/CN101804096B/en 2010-08-18 Publication of CN101804096A publication Critical patent/CN101804096A/en 2011-11-09 Application granted granted Critical 2011-11-09 Publication of CN101804096B publication Critical patent/CN101804096B/en Status Expired - Fee Related legal-status Critical Current 2030-02-08 Anticipated expiration legal-status Critical Links Espacenet Global Dossier Discuss 229930013930 alkaloid Natural products 0.000 title claims abstract description 128 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 75 238000000034 method Methods 0.000 title claims abstract description 33 244000107975 Strychnos nux-vomica Species 0.000 title description 61 LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49 YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 27 239000000843 powder Substances 0.000 claims abstract description 22 239000006228 supernatant Substances 0.000 claims abstract description 19 VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 16 239000000284 extract Substances 0.000 claims abstract description 15 238000000605 extraction Methods 0.000 claims abstract description 9 239000002904 solvent Substances 0.000 claims abstract description 3 239000002244 precipitate Substances 0.000 claims abstract 2 HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15 239000003814 drug Substances 0.000 claims description 12 238000010992 reflux Methods 0.000 claims description 9 239000000463 material Substances 0.000 claims description 8 238000002360 preparation method Methods 0.000 claims description 8 238000010438 heat treatment Methods 0.000 claims description 5 238000001035 drying Methods 0.000 claims description 3 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2 239000012675 alcoholic extract Substances 0.000 claims 2 229940035676 analgesics Drugs 0.000 claims 1 239000000730 antalgic agent Substances 0.000 claims 1 230000000118 anti-neoplastic effect Effects 0.000 claims 1 238000005119 centrifugation Methods 0.000 claims 1 239000012141 concentrate Substances 0.000 claims 1 229940124622 immune-modulator drug Drugs 0.000 claims 1 QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical class O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 abstract description 56 QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 abstract description 28 241001279009 Strychnos toxifera Species 0.000 abstract description 27 229960005453 strychnine Drugs 0.000 abstract description 27 238000002474 experimental method Methods 0.000 abstract description 16 231100000419 toxicity Toxicity 0.000 abstract description 8 230000001988 toxicity Effects 0.000 abstract description 8 230000000202 analgesic effect Effects 0.000 abstract description 7 230000000259 anti-tumor effect Effects 0.000 abstract description 5 230000000144 pharmacologic effect Effects 0.000 abstract description 5 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4 238000011156 evaluation Methods 0.000 abstract description 2 238000004519 manufacturing process Methods 0.000 abstract description 2 230000009286 beneficial effect Effects 0.000 abstract 1 230000005965 immune activity Effects 0.000 abstract 1 210000000582 semen Anatomy 0.000 description 47 241000699670 Mus sp. Species 0.000 description 32 238000005303 weighing Methods 0.000 description 14 241000699666 Mus Species 0.000 description 12 210000004027 cell Anatomy 0.000 description 12 239000000243 solution Substances 0.000 description 12 241001465754 Metazoa Species 0.000 description 11 IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8 206010014025 Ear swelling Diseases 0.000 description 8 241001113787 Strychnos Species 0.000 description 8 238000004090 dissolution Methods 0.000 description 8 230000000857 drug effect Effects 0.000 description 8 239000007924 injection Substances 0.000 description 8 238000002347 injection Methods 0.000 description 8 239000002253 acid Substances 0.000 description 7 230000001476 alcoholic effect Effects 0.000 description 7 239000003153 chemical reaction reagent Substances 0.000 description 7 239000000706 filtrate Substances 0.000 description 7 238000004128 high performance liquid chromatography Methods 0.000 description 7 238000000746 purification Methods 0.000 description 7 238000001291 vacuum drying Methods 0.000 description 7 VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 5 230000037396 body weight Effects 0.000 description 5 230000000052 comparative effect Effects 0.000 description 5 238000001914 filtration Methods 0.000 description 5 239000013641 positive control Substances 0.000 description 5 CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4 239000000980 acid dye Substances 0.000 description 4 238000004737 colorimetric analysis Methods 0.000 description 4 230000006837 decompression Effects 0.000 description 4 230000000694 effects Effects 0.000 description 4 210000000056 organ Anatomy 0.000 description 4 238000004064 recycling Methods 0.000 description 4 239000009306 yunnan baiyao Substances 0.000 description 4 -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 3 208000002193 Pain Diseases 0.000 description 3 230000036592 analgesia Effects 0.000 description 3 239000002260 anti-inflammatory agent Substances 0.000 description 3 238000006243 chemical reaction Methods 0.000 description 3 UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3 229960003957 dexamethasone Drugs 0.000 description 3 229940079593 drug Drugs 0.000 description 3 210000005069 ears Anatomy 0.000 description 3 239000002609 medium Substances 0.000 description 3 238000011160 research Methods 0.000 description 3 230000004044 response Effects 0.000 description 3 210000000952 spleen Anatomy 0.000 description 3 230000008961 swelling Effects 0.000 description 3 210000001541 thymus gland Anatomy 0.000 description 3 QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2 CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2 208000006820 Arthralgia Diseases 0.000 description 2 102000004190 Enzymes Human genes 0.000 description 2 108090000790 Enzymes Proteins 0.000 description 2 231100000111 LD50 Toxicity 0.000 description 2 206010070834 Sensitisation Diseases 0.000 description 2 238000002835 absorbance Methods 0.000 description 2 239000002246 antineoplastic agent Substances 0.000 description 2 239000013078 crystal Substances 0.000 description 2 230000035617 depilation Effects 0.000 description 2 239000007928 intraperitoneal injection Substances 0.000 description 2 239000007788 liquid Substances 0.000 description 2 238000002156 mixing Methods 0.000 description 2 230000036407 pain Effects 0.000 description 2 238000001556 precipitation Methods 0.000 description 2 238000004321 preservation Methods 0.000 description 2 230000008313 sensitization Effects 0.000 description 2 210000002784 stomach Anatomy 0.000 description 2 UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2 231100000331 toxic Toxicity 0.000 description 2 230000002588 toxic effect Effects 0.000 description 2 240000006409 Acacia auriculiformis Species 0.000 description 1 BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1 208000010392 Bone Fractures Diseases 0.000 description 1 206010009944 Colon cancer Diseases 0.000 description 1 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1 206010013183 Dislocation of vertebra Diseases 0.000 description 1 239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1 208000004929 Facial Paralysis Diseases 0.000 description 1 206010017076 Fracture Diseases 0.000 description 1 240000004859 Gamochaeta purpurea Species 0.000 description 1 241001299553 Ilex chinensis Species 0.000 description 1 241001100935 Ilex purpurea Species 0.000 description 1 235000003366 Ilex purpurea Nutrition 0.000 description 1 206010062717 Increased upper airway secretion Diseases 0.000 description 1 206010061218 Inflammation Diseases 0.000 description 1 241001113846 Loganiaceae Species 0.000 description 1 206010058467 Lung neoplasm malignant Diseases 0.000 description 1 206010068319 Oropharyngeal pain Diseases 0.000 description 1 208000000114 Pain Threshold Diseases 0.000 description 1 241000282376 Panthera tigris Species 0.000 description 1 206010033888 Paraphilia Diseases 0.000 description 1 229930182555 Penicillin Natural products 0.000 description 1 JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1 201000007100 Pharyngitis Diseases 0.000 description 1 208000025747 Rheumatic disease Diseases 0.000 description 1 208000005718 Stomach Neoplasms Diseases 0.000 description 1 102000004142 Trypsin Human genes 0.000 description 1 108090000631 Trypsin Proteins 0.000 description 1 208000037386 Typhoid Diseases 0.000 description 1 208000036826 VIIth nerve paralysis Diseases 0.000 description 1 206010047700 Vomiting Diseases 0.000 description 1 210000001015 abdomen Anatomy 0.000 description 1 230000003187 abdominal effect Effects 0.000 description 1 229960000583 acetic acid Drugs 0.000 description 1 229960001138 acetylsalicylic acid Drugs 0.000 description 1 239000004480 active ingredient Substances 0.000 description 1 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1 238000010171 animal model Methods 0.000 description 1 230000000954 anitussive effect Effects 0.000 description 1 230000000146 antalgic effect Effects 0.000 description 1 230000000844 anti-bacterial effect Effects 0.000 description 1 229940121363 anti-inflammatory agent Drugs 0.000 description 1 230000001741 anti-phlogistic effect Effects 0.000 description 1 229940034982 antineoplastic agent Drugs 0.000 description 1 229940041181 antineoplastic drug Drugs 0.000 description 1 229940124584 antitussives Drugs 0.000 description 1 230000017531 blood circulation Effects 0.000 description 1 244000309466 calf Species 0.000 description 1 238000004113 cell culture Methods 0.000 description 1 230000004663 cell proliferation Effects 0.000 description 1 230000007969 cellular immunity Effects 0.000 description 1 229960004316 cisplatin Drugs 0.000 description 1 DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1 208000029742 colonic neoplasm Diseases 0.000 description 1 238000005520 cutting process Methods 0.000 description 1 230000009849 deactivation Effects 0.000 description 1 230000007423 decrease Effects 0.000 description 1 238000010790 dilution Methods 0.000 description 1 239000012895 dilution Substances 0.000 description 1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1 201000010099 disease Diseases 0.000 description 1 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1 230000003203 everyday effect Effects 0.000 description 1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1 201000006585 gastric adenocarcinoma Diseases 0.000 description 1 206010017758 gastric cancer Diseases 0.000 description 1 239000012362 glacial acetic acid Substances 0.000 description 1 239000011521 glass Substances 0.000 description 1 239000001963 growth medium Substances 0.000 description 1 206010073071 hepatocellular carcinoma Diseases 0.000 description 1 235000008216 herbs Nutrition 0.000 description 1 230000002519 immonomodulatory effect Effects 0.000 description 1 230000036039 immunity Effects 0.000 description 1 230000003053 immunization Effects 0.000 description 1 238000002649 immunization Methods 0.000 description 1 239000002955 immunomodulating agent Substances 0.000 description 1 230000002584 immunomodulator Effects 0.000 description 1 229940121354 immunomodulator Drugs 0.000 description 1 230000007365 immunoregulation Effects 0.000 description 1 230000001506 immunosuppresive effect Effects 0.000 description 1 238000000338 in vitro Methods 0.000 description 1 238000009776 industrial production Methods 0.000 description 1 230000004054 inflammatory process Effects 0.000 description 1 230000002401 inhibitory effect Effects 0.000 description 1 230000005764 inhibitory process Effects 0.000 description 1 231100000636 lethal dose Toxicity 0.000 description 1 230000031700 light absorption Effects 0.000 description 1 201000005296 lung carcinoma Diseases 0.000 description 1 239000002398 materia medica Substances 0.000 description 1 239000012567 medical material Substances 0.000 description 1 239000012528 membrane Substances 0.000 description 1 206010028417 myasthenia gravis Diseases 0.000 description 1 230000010355 oscillation Effects 0.000 description 1 238000000643 oven drying Methods 0.000 description 1 230000037040 pain threshold Effects 0.000 description 1 229940049954 penicillin Drugs 0.000 description 1 208000026435 phlegm Diseases 0.000 description 1 239000006187 pill Substances 0.000 description 1 238000012545 processing Methods 0.000 description 1 230000035484 reaction time Effects 0.000 description 1 230000000552 rheumatic effect Effects 0.000 description 1 210000002966 serum Anatomy 0.000 description 1 230000001954 sterilising effect Effects 0.000 description 1 238000004659 sterilization and disinfection Methods 0.000 description 1 201000011549 stomach cancer Diseases 0.000 description 1 238000003860 storage Methods 0.000 description 1 229960005322 streptomycin Drugs 0.000 description 1 239000007929 subcutaneous injection Substances 0.000 description 1 238000010254 subcutaneous injection Methods 0.000 description 1 238000012360 testing method Methods 0.000 description 1 231100000027 toxicology Toxicity 0.000 description 1 239000012588 trypsin Substances 0.000 description 1 210000004881 tumor cell Anatomy 0.000 description 1 201000008297 typhoid fever Diseases 0.000 description 1 230000008673 vomiting Effects 0.000 description 1 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1 Landscapes Medicines Containing Plant Substances ( AREA ) Pharmaceuticals Containing Other Organic And Inorganic Compounds ( AREA ) Abstract Translated from Chinese 本发明公开了一种除去马钱子总生物碱中部分士的宁而得到纯化马钱子总生物碱的方法。该方法先采用一定浓度乙醇提取，然后将提取物用盐酸溶解，溶解后将pH调为碱性，再用二氯甲烷萃取、减压除去溶剂得到马钱子总生物碱；然后将马钱子总生物碱粉末用乙醇超声溶解，减压浓缩至一定体积，将浓缩液离心取上清液后，冷藏静置除去沉淀，把上清液干燥得纯化马钱子总生物碱。采用本发明方法提取纯化马钱子总生物碱士的宁的含量下降显著，提取过程安全，成本低，有利于工业化规模生产。经药理实验评价结果表明：纯化马钱子总生物碱的镇痛、抗炎、免疫、抗肿瘤活性均显著优于马钱子总生物碱，而毒性明显下降。 The invention discloses a method for obtaining purified total strychnine alkaloids by removing part of strychnine in the total strychnine alkaloids. The method first uses a certain concentration of ethanol to extract, then dissolves the extract with hydrochloric acid, adjusts the pH to alkaline after dissolving, then extracts with dichloromethane, and removes the solvent under reduced pressure to obtain the total alkaloids of Nuxychnami; The total alkaloid powder is ultrasonically dissolved with ethanol, concentrated under reduced pressure to a certain volume, and the concentrated solution is centrifuged to obtain the supernatant, then refrigerated to remove the precipitate, and the supernatant is dried to obtain the purified total alkaloids of Strychnis chinensis. The content of the total alkaloid strychnine extracted and purified by the method of the invention is significantly reduced, the extraction process is safe, the cost is low, and it is beneficial to industrial scale production. The evaluation results of pharmacological experiments show that the analgesic, anti-inflammatory, immune and anti-tumor activities of the purified total alkaloids of Nuxychnium are significantly better than those of the total alkaloids of Nuxychnium, while the toxicity is significantly reduced. Description A kind ofly extract the method for purified total alkaloid of strychnos nux-vomica and the application in pharmacy thereof One, technical field The present invention relates to a kind of method for extraction and purification of active ingredient of Chinese herbs, specifically relate to remove the method for extraction and purification of the purified total alkaloid of strychnos nux-vomica that obtains behind the part strychnine and the application in pharmacy thereof. Two, technical background Semen Strychni has another name called vomiting nut, beginning is stated from " Compendium of Materia Medica rolls up 18 ", it is the dry mature seed of loganiaceae plant Semen Strychni (Strychnounux-vomica L.), effect with removing obstruction in the collateral to relieve pain, mass dissipating and swelling eliminating, be commonly used to treat sore throat, toxic swelling, rheumatic arthralgia, fracture, facial paralysis, diseases such as myasthenia gravis on the tcm clinical practice.Compendium of Material Medica is sayed that it can be controlled in the Chinese patent medicines such as " mass in the abdomen disappears for typhoid fever calentura, throat arthralgia pain " as drug for invigorating blood circulation and eliminating stasis, be everlasting " JIUFEN POWDER ", " dispelling wind Pain-Stopping Pill ", " tiger strong ball ", " Green Dragon ball " and is used. Total alkaloids is a topmost effective site in the Semen Strychni, and present studies show that: have 16 kinds of alkaloid components in the total alkaloids in Semen Strychni at least, main component is strychnine and strychnine.Strychnine has very strong pharmacologically actives such as antalgic and inflammation relieving as one of main component of Semen Strychni, and be usually used in antitussive clinically, eliminate the phlegm, antibacterial and antitumor, and another main component Strychnine Content account for total alkaloids pact half, but pharmacologically active is relatively low, is the main toxic component of Semen Strychni.Total alkaloids in Semen Strychni is applied to clinical biggest obstacle and is to have intensive nervus centralis toxicity. Have document (cross the China etc. of shaking, the research of Semen Strychni pharmacological toxicology is looked back and the safety research prospect, combination of Chinese and Western medicine journal, 2008,6 (6): 645-649) report strychnine and strychnine are given mouse stomach, LD 50 Be respectively 3.27mgkg -1 And 233mgkg -1 , lumbar injection is 1.53mgkg -1 And 69mgkg -1 Therefore if can remove part strychnine in the total alkaloids, then can reduce its toxicity, can keep its original pharmacologically active substantially again, improve clinical application safety.It must be noted that, can realize that cost is very high, other alkaloid component loss simultaneously is also big, and is difficult to realize large-scale industrial production, therefore, removes the part strychnine and has more feasibility and application prospect though all remove strychnine.So far do not appear in the newspapers about the method for removing the part strychnine in the total alkaloids in Semen Strychni. Three, summary of the invention 1, goal of the invention The object of the present invention is to provide a kind of method of removing the purified total alkaloid of strychnos nux-vomica of part strychnine. Purified total alkaloid of strychnos nux-vomica provided by the present invention is compared with the total alkaloids in Semen Strychni of not removing the part strychnine, pharmacological action at aspects such as analgesia, antiinflammatory, immunity, antitumor significantly improves, and toxicity significantly descends, and is easy to realize suitability for industrialized production. 2, technical scheme The objective of the invention is to adopt following technical proposal to realize: A kind of method of extracting purified total alkaloid of strychnos nux-vomica is characterized in that step is as follows: (1) with the Semen Strychni medical material, is ground into coarse powder, takes by weighing 100-200 gram coarse powder; (2) with the alcohol reflux of 1000-2000ml, decompression recycling ethanol gets pure extractum; (3) with the above-mentioned pure extractum of dissolving with hydrochloric acid of 400-1000ml, centrifugal, get supernatant; (4) add sodium hydroxide, the adjusting pH value is 10-14, and the dichloromethane of this solution with 500-2000ml extracted, and removal of solvent under reduced pressure gets the total alkaloids in Semen Strychni powder; (5) with above-mentioned total alkaloids in Semen Strychni powder, with 1000-3000ml50-90% ethanol ultrasonic dissolution; (6) 0.4-0.05 that is evaporated to original volume doubly, centrifugal concentrated solution is got supernatant; (7) supernatant cold preservation is left standstill the centrifugal precipitation of removing, the dry purified total alkaloid of strychnos nux-vomica that gets of supernatant then. Concentration of alcohol described in the step (2) is 50-95%, and the reflux number of times is 1-5 time, and each reflux time is 0.5-2h. Concentration of hydrochloric acid described in the step (3) is 0.1-1mol/L. Refrigerated storage temperature described in the step (7) is 0-10 ℃, and described drying means is constant pressure and dry or vacuum drying. The application of described extracting method gained purified total alkaloid of strychnos nux-vomica in the preparation analgesic. The application of described extracting method gained purified total alkaloid of strychnos nux-vomica in the preparation anti-inflammatory drug. The application of described extracting method gained purified total alkaloid of strychnos nux-vomica in the preparation antitumor drug. The application of described extracting method gained purified total alkaloid of strychnos nux-vomica in the preparation immunoregulation medicament. The purified total alkaloid of strychnos nux-vomica that the present invention extracts can be used to prepare analgesic, anti-inflammatory agent, antineoplastic agent, immunomodulator.But more than use oral administration, lumbar injection and percutaneous administration. We find that total alkaloids in Semen Strychni and strychnine dissolubility in finite concentration ethanol differs very big, utilize the difference of this dissolution properties can realize keeping total alkaloids in Semen Strychni and remove the part strychnine.Not removing the total alkaloids in Semen Strychni of part strychnine before purified total alkaloid of strychnos nux-vomica that pharmacological evaluation shows acquisition that the present invention extracts and purification compares, pharmacological action at aspects such as analgesia, antiinflammatory, antitumor, immunomodulating significantly strengthens, and toxicity significantly descends. The content of strychnine measures wherein with the HPLC method that the content of strychnine reaches 44%～52% in the total alkaloids in Semen Strychni before the purification, the content of promptly removing strychnine in the purified total alkaloid of strychnos nux-vomica that obtains behind the part strychnine through the extraction purification is 14%～23%, and the purity of measuring purified total alkaloid of strychnos nux-vomica with acid-dye colorimetry is 75%～90%. Four, the specific embodiment Further illustrate content of the present invention below in conjunction with example, but these embodiment do not limit protection scope of the present invention. Embodiment 1: the method for extracting purified total alkaloid of strychnos nux-vomica: (1) takes by weighing Semen Strychni, pulverize, sieve, make coarse powder, take by weighing the 200g coarse powder; (2) extract with 70% alcohol heating reflux, each 1000mL extracts 1h, extracts altogether 3 times, filters, and merges three times filtrate, and decompression recycling ethanol gets pure extractum; (3) with 1mol/L hydrochloric acid 400mL ultrasonic dissolution, the centrifugal 10min of 4000rpmin takes out supernatant; (4) regulate pH to 12 with sodium hydroxide, divide 5 extractions, merge with the 2000mL dichloromethane, vacuum drying is removed dichloromethane, and weight decided in accurate title, obtain the total alkaloids in Semen Strychni powder, measuring wherein with the HPLC method, strychnine content accounts for 52% of total alkaloids in Semen Strychni; (5) with above-mentioned gained total alkaloids in Semen Strychni powder ultrasonic dissolution in 2000mL 50% ethanol; (6) put and revolve 0.05 times that steams to original volume on the Rotary Evaporators, have a large amount of white crystals to separate out on the visible flask walls, pour out concentrated solution, 4000rpm, centrifugal 10min gets supernatant; (7) supernatant is put 4 ℃ of standing over night, 4000rpm, centrifugal 10min, discard precipitation, supernatant is put the vacuum drying oven drying, and precision is weighed, and gets purified total alkaloid of strychnos nux-vomica, measure wherein with the HPLC method that the content of strychnine accounts for 23% of purified total alkaloid of strychnos nux-vomica, the purity that acid-dye colorimetry is measured purified total alkaloid of strychnos nux-vomica is 90%. Embodiment 2: the method for extracting purified total alkaloid of strychnos nux-vomica: (1) takes by weighing Semen Strychni, pulverize, sieve, make coarse powder, take by weighing the 200g coarse powder; (2) extract with 90% alcohol heating reflux, each 2000mL extracts 2h, extracts altogether 2 times, filter, and merging filtrate, decompression recycling ethanol gets pure extractum; (3) with 0.2mol/L hydrochloric acid 1000mL ultrasonic dissolution, sucking filtration gets filtrate; (4) regulate pH to 14 with sodium hydroxide, divide 3 extractions, merge with the 1000mL dichloromethane, reclaim under reduced pressure is removed dichloromethane, and weight decided in the precision title, obtains total alkaloids in Semen Strychni, and the HPLC method measures wherein that strychnine content accounts for 46% of total alkaloids in Semen Strychni; (5) with above-mentioned gained total alkaloids in Semen Strychni powder ultrasonic dissolution in 3000mL 70% ethanol; (6) vacuum drying takes out concentrated solution to 0.2 times of original volume, and the centrifugal 10min of 4000rpm gets supernatant; (7) supernatant is put 0 ℃ of standing over night, sucking filtration is got filtrate in the dry pressed powder that gets of vacuum drying oven, precision is weighed, get purified total alkaloid of strychnos nux-vomica, the HPLC method measures wherein that strychnine accounts for 14% of purified total alkaloid of strychnos nux-vomica, and the purity that acid-dye colorimetry is measured purified total alkaloid of strychnos nux-vomica is 84%. Embodiment 3: the method for extracting purified total alkaloid of strychnos nux-vomica: (1) takes by weighing Semen Strychni, pulverize, sieve, make coarse powder, take by weighing the 100g coarse powder; (2) extract with 50% alcohol heating reflux, each 1000mL extracts 1h, extracts altogether 4 times, filter, and merging filtrate, decompression recycling ethanol gets pure extractum; (3) with 0.5mol/L hydrochloric acid 400mL ultrasonic dissolution, sucking filtration gets filtrate; (4) regulate pH to 10 with sodium hydroxide, divide 4 extractions, merge with the 500mL dichloromethane, reclaim under reduced pressure is removed dichloromethane, and weight decided in the precision title, obtains total alkaloids in Semen Strychni, and the HPLC method measures wherein that strychnine content accounts for 44% of total alkaloids in Semen Strychni; (5) with above-mentioned gained total alkaloids in Semen Strychni powder ultrasonic dissolution in 1000mL 75% ethanol; (6) vacuum drying takes out concentrated solution to 0.1 times of original volume, and the centrifugal 10min of 4000rpm gets supernatant; (7) supernatant is put 8 ℃ of standing over night, sucking filtration is got filtrate in the dry pressed powder that gets of vacuum drying oven, precision is weighed, get purified total alkaloid of strychnos nux-vomica, the HPLC method measures wherein that strychnine accounts for purified total alkaloid of strychnos nux-vomica 21%, and the purity that acid-dye colorimetry is measured purified total alkaloid of strychnos nux-vomica is 75%. Embodiment 4: the toxicity research of purified total alkaloid of strychnos nux-vomica---and the acute toxicity testing to mice carries out evaluating drug effect to embodiment 1 gained purified total alkaloid of strychnos nux-vomica: 1. experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of,, be mixed with a series of concentration with containing 20% alcoholic acid PBS (pH=7.4) dissolving. 1.2 reagent: ethanol. 1.3 animal: the ICR mice, body weight 18～22g, ♀ ♂ half and half is provided by Yangzhou University comparative medicine center. 2. method and result Trial test: at first find out 0% and 100% estimate lethal dose (Dn, Dm).At first use a series of medicinal liquids of 2 times of dilutions, respectively try 4 mices with 0.2mL/10g dosage, and then cause death between the group, insert 3～5 grades of dosage by the geometric ratio grade again 4/4 and 0/4, dosage successively decreases with 0.14mL, 0.1mL, 0.07mL, 0.05mL, 0.035mL by every 10g, respectively tries 4 mices again.If certain group mortality rate is 4/4, its last group is 2/4 or 3/4, is Dm with this group dosage then; If last group is 0/4 or 1/4, then 1.5 times with this group dosage are Dm.Find out Dn with method. Grouping: packet count is 4～9 groups, guarantees minimum dose group 100% animals survived. Formal experiment: the medicine that gives respectively to organize variable concentrations by the 0.2mL/10g dosage.Add up every group of mortality rate and ask the median lethal dose(LD 50) of calculating every kind of medicine. Result: the LD of mouse peritoneal injection purified total alkaloid of strychnos nux-vomica 50 Be 12.303mgkg -1 , LD 50 95% fiducial limit scope be: 12.303 ± 2.098mgkg -1 The LD of mouse peritoneal injection total alkaloids in Semen Strychni 50 Be 6.400mgkg -1 , LD 50 95% fiducial limit scope be: 6.400 ± 0.726mgkg -1 As seen the toxicity of purified total alkaloid of strychnos nux-vomica has descended about 1.9 times, and toxicity significantly reduces. Embodiment 5: the analgesic activity of purified total alkaloid of strychnos nux-vomica---the mouse writhing experiment Embodiment 1 gained purified total alkaloid of strychnos nux-vomica is carried out evaluating drug effect: 1. experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of, with containing 20% alcoholic acid PBS (pH=7.4) dissolving, concentration is 1mgmL -1 Aspirin. 1.2 reagent: ethanol, glacial acetic acid. 1.3 animal: the ICR mice, body weight 18～22g, ♀ ♂ half and half is provided by Yangzhou University comparative medicine center. 2. method and result Experiment mice is divided into 6 groups at random, 10 every group.Irritate stomach for every treated animal and give purified total alkaloid of strychnos nux-vomica solution, total alkaloids in Semen Strychni solution, aspirin solution, the blank group is given equivalent PBS (containing 20% ethanol), respectively organize mice lumbar injection 0.6% acetum (0.2mL/10g) respectively after the administration behind the 30min, observe the number of times that writhing response appears in the interior mice of 25min, record, and the analgesia percentage rate of calculating medicine.The results are shown in Table 1. Table 1 different dosing dosage to Dichlorodiphenyl Acetate cause mouse writhing reaction influence (X ± S, n=10) Annotate: compare with the blank group △ P＜0.05 The result of table 1 shows: what positive controls can reduce mice turns round the body number of times, with the blank group significant difference is arranged relatively; The effective dose of purified total alkaloid of strychnos nux-vomica is 12mgkg -1 But middle dosage group and low dose group do not have effect.And total alkaloids in Semen Strychni is at 12mgkg -1 Relatively do not have significant difference with the blank group, the analgesic effect of prompting purified total alkaloid of strychnos nux-vomica is better than total alkaloids in Semen Strychni. Embodiment 6: the analgesic activity of purified total alkaloid of strychnos nux-vomica---the experiment of mice hot plate Embodiment 1 gained purified total alkaloid of strychnos nux-vomica is carried out evaluating drug effect: 1. experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of, with containing 20% alcoholic acid PBS (pH=7.4) dissolving, concentration is 1mgmL -1 YUNNAN BAIYAO DING. 1.2 reagent: ethanol. 1.3 instrument: HH-8 type digital display thermostat water bath, state China Electrical Appliances Co., Ltd. 1.4 animal: the ICR mice, body weight 18～22g, ♀ is provided by Yangzhou University comparative medicine center. 2. method and result The rosette of a diameter 10cm is put into 55 ± 0.5 ℃ of water-baths, on disk, place the glass cylinder that 15cm is high, during mensuration mice is placed on rapidly on the disk, picks up counting, lick metapedes or jump out of rosette until animal from touching rosette.Still reactionless as surpassing 30s, then immediately mice is taken out in case the animal of burning, and count the response time (s).Get 60 mices, be divided into 6 groups (blank group, positive controls, each 10 of high, medium and low three the dosage groups of purified total alkaloid of strychnos nux-vomica, total alkaloids in Semen Strychni groups) at random, 24h before the experiment, to the mouse web portion depilation, depilation area 2 * 2cm 2 , standby.Before the administration, measure the basic reaction time (s) of respectively organizing mice, smear purified total alkaloid of strychnos nux-vomica solution, total alkaloids in Semen Strychni solution, YUNNAN BAIYAO DING in every treated animal abdominal part, the blank group is smeared equivalent PBS (containing 20% ethanol), administration is 3 times altogether, each 10min at interval, last administration 15min, 45min, 75min measure its response time once more, the results are shown in Table 2. The influence that table 2. different dosing dosage reacts the mice thermostimulation (X ± S, n=10) Annotate: with comparison before the administration 1) P＜0.05, 2) P＜0.01, 3) P＜0.001 The result of table 2 shows: positive controls can significantly improve the mice pain threshold, with the blank group significant difference is arranged relatively; The effective dose of purified total alkaloid of strychnos nux-vomica is 12mgkg -1 But middle dosage group and low dose group do not have effect.And total alkaloids in Semen Strychni is at 12mgkg -1 Relatively do not have significant difference with the blank group, the analgesic effect of prompting purified total alkaloid of strychnos nux-vomica is better than total alkaloids in Semen Strychni. Embodiment 7: the antiinflammatory action of purified total alkaloid of strychnos nux-vomica---the mice ear experiment Embodiment 1 gained purified total alkaloid of strychnos nux-vomica is carried out evaluating drug effect: 1. experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of, with containing 20% alcoholic acid PBS (pH=7.4) dissolving, concentration is 1mgmL -1 YUNNAN BAIYAO DING. 1.2 reagent: ethanol, dimethylbenzene. 1.3 instrument: electronic scale, card punch. 1.4 animal: the ICR mice, body weight 18～22g, ♀ ♂ half and half is provided by Yangzhou University comparative medicine center. 2. method and result Get 60 mices, be divided into 6 groups (blank group, positive controls, each 10 of high, medium and low three the dosage groups of purified total alkaloid of strychnos nux-vomica, total alkaloids in Semen Strychni groups) at random.Mouse right ear is smeared 20 μ L dimethylbenzene, and left ear is not coated with in contrast, behind the 30min, each is organized about mice two ears and all smears and be subjected to the reagent thing accordingly, blank group contains 20% alcoholic acid PBS, and the administration group gives purified total alkaloid of strychnos nux-vomica, and administration is 3 times altogether, each 80 μ L, each 10min at interval behind the last administration 40min puts to death the dislocation of mice cervical region two ears about cutting along auricle, with the card punch of diameter 6mm about two ear same area lay round auricle, weigh. Ear swelling degree=auris dextra weight-left ear is heavy Press down swollen rate=(blank group average ear swelling degree-average ear swelling degree of administration group)/average ear swelling degree of blank group The results are shown in Table 3. Table 3 different dosing dosage is to antiphlogistic influence Annotate: compare with the blank group △ P＜0.05, △ △ P＜0.01, △ △ △ P＜0.001, YUNNAN BAIYAO group administration volume is 240 μ L Table 3 is the result show, positive controls can obviously suppress the ear swelling of mice, compares significant difference (P＜0.001) with the blank group, shows the modeling success.The total alkaloids in Semen Strychni group does not relatively have significant difference with blank group, and purified total alkaloid of strychnos nux-vomica high dose group and middle dosage group and blank group are relatively, and difference also has significance (P＜0.05), the low dose group zero difference. Embodiment 8: the immunization of purified total alkaloid of strychnos nux-vomica---the experiment of mice delayed hypersensitivity Embodiment 1 gained purified total alkaloid of strychnos nux-vomica is carried out evaluating drug effect: 1. experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of, with containing 20% alcoholic acid PBS (pH=7.4) dissolving, concentration is 1mgmL -1 Dexamethasone. 1.2 reagent: ethanol, dinitrochlorobenzene, acetone. 1.3 animal: the ICR mice, body weight 18～22g, ♀ ♂ half and half is provided by Yangzhou University comparative medicine center. 2. method and result Laboratory animal is handled: get the ICR mice, be divided into 7 groups at random, every group 10, be two kinds of administering modes of percutaneous and lumbar injection, the administration of percutaneous mode be divided into dosage group, purified total alkaloid of strychnos nux-vomica high dose group in blank group, purified total alkaloid of strychnos nux-vomica low dose group, the purification strychnine total alkaloids, 24h scrapes unhairing, the about 2 * 2cm of area with the blade after lubricated before positive group of intraperitoneal injection, every group of mouse web portion administration of percutaneous 2 Draw medicinal liquid with pipettor and evenly be applied to mouse web portion for every group of percutaneous dosing during administration, blank group is coated with and contains 20% alcoholic acid PBS in contrast, and three groups of dosage of the basic, normal, high dosage of purified total alkaloid of strychnos nux-vomica are respectively 3mgmL -1 , 6mgmL -1 , 12mgmL -1 , total alkaloids in Semen Strychni group dosage is 12mgmL -1 Every group of lumbar injection gives dexamethasone, and dosage is 12mgmL -1 Every group of every day be administered once successive administration 10 days. Sensitization: after the administration in first day, every group of mice used the DNCB solution 50 μ L sensitization of microsyringe back subcutaneous injection 3%, and after administration in the 4th day, same operation is strengthened once again. The generation and the mensuration of DTH reaction: administration the 10th day, 1%DNCB solution 20 μ L are applied to mouse right ear (two sides) attack, attack back 24h, mice is put to death in the cervical vertebra dislocation, cut left and right sides auricular concha, take off auricle at identical position, scales/electronic balance weighing with the card punch of diameter 6mm.Getting mouse thymus simultaneously and spleen is weighed, is the swelling degree with the difference of left and right sides auricle weight, and heavy and thymus recast is spleen index and thymus index with the spleen of every 10g mice respectively, observes difference that each is organized.The results are shown in Table 4,5. Table 4 purified total alkaloid of strychnos nux-vomica to dinitrochlorobenzene induce the ear swelling degree of tardy paraphilia reaction mice influence (X ± S, n=10) Annotate: compare with the blank group △ P＜0.05, △ △ P＜0.01, △ △ △ P＜0.001 Experimental results show that, the purified total alkaloid of strychnos nux-vomica high dose group of percutaneous dosing can obviously suppress DNCB induced mice ear swelling degree, compare with the blank group, significant difference (p＜0.01), but middle dosage and low dosage purified total alkaloid of strychnos nux-vomica group compare zero difference with blank group.The dexamethasone of intraperitoneal injection and blank comparing difference be (p＜0.001) significantly, and the purified total alkaloid of strychnos nux-vomica that prompting reaches doses can obviously alleviate the ear swelling degree of mice, and the pair cell immunity has inhibitory action. Table 5 purified total alkaloid of strychnos nux-vomica to mouse immune organ weight's influence (X ± S, n=10) Annotate: with blank group separately relatively: △ △ P＜0.01 The experiment proved that, with blank group comparison separately, the purification Strychnos alkaloid of high, medium and low three the dosage groups of percutaneous dosing and Strychnos alkaloid group do not have obvious influence (p＞0.05) to the ponderal index of immune organ, and lumbar injection group dexamethasone has the effect (p＜0.01) that suppresses immune organ extremely significantly.The administration of prompting short-term, purified total alkaloid of strychnos nux-vomica has immunosuppressive action, but the weight of immune organ is not had influence. Embodiment 9: the antitumor action of purified total alkaloid of strychnos nux-vomica---and the influence to the tumor cell of In vitro culture is carried out evaluating drug effect to embodiment 1 gained purified total alkaloid of strychnos nux-vomica: 1 experiment material 1.1 sample: take by weighing total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica is an amount of, with dimethyl sulfoxide (DMSO) hydrotropy, the DMSO ultimate density is no more than 1.0%.0.22 μ m microporous filter membrane (GVMP 01230, Millipore, and USA) filtration sterilization, 4 ℃ of preservations are stand-by; Cisplatin. 1.2 reagent: DMEM culture medium (GIBCO, the U.S.); Newborn calf serum (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims) (56 ℃ of water-bath deactivation 0.5h); Trypsin AMRESCO, the U.S.); MTT (AMRESCO, the U.S.); Penicillin, streptomycin (Lukang Medical Co., Ltd., Shandong) 1.3 instrument: CO 2 Cell culture incubator (FORMA SCIENTIFIC, the U.S.); Enzyme mark spectrophotometric is read plate instrument (Bio-RAD, Model 680, the U.S.) 1.4 cell: human hepatoma cell strain SMMC-7721, HepG2, human stomach cancer cell line MGC-803 are available from Nanjing KaiJi Biology Science Development Co., Ltd; Human lung carcinoma cell line A549 is so kind as to give by doctor Zhang Xu of preclinical medicine institute of Nanjing University of Traditional Chinese Medicine; Human colon cancer cell strain LoVo is so kind as to give by professor Cai Yunqing of Nanjing Medical University; People's adenocarcinoma of stomach cell strain SGC-7901 is so kind as to give by Nanjing drum tower doctor Li Rutian of hospital; Human oophoroma cell line A2780 is provided by Jiangsu TCM Hospital. 2 methods and result Get the various cancerous cell that are in exponential phase, insert (cell density 6 * 10 in 96 orifice plates 4 Cells/ml), every hole 80 μ l.Merge to 60-70% dosing processing at cell attachment and growth, every kind of medicine is established 5 Concentraton gradient, and (the medicine final concentration: total alkaloids in Semen Strychni, purified total alkaloid of strychnos nux-vomica are 200,100,50,25,12.5ugmL -1 Cisplatin is 20,10,5,2.5,1.25ugmL -1 ) every kind of concentration establishes four multiple holes.Behind 72h, every hole adds MTT (5mgmL -1 ) 20 μ l, behind the mixing of plane, place incubator to continue to hatch 4h, discard the supernatant in each hole then, add 150 μ l DMSO again, planar oscillation mixing 10min, after treating that purple crystal in its each hole dissolves fully, place enzyme mark spectrophotometric to read light absorption value (A, the λ in each hole of the mensuration plate instrument under 490nm ).Calculate cell proliferation inhibition rate IR:IR (%)=(1-administration group absorbance/blank group absorbance) * 100% by following formula.The experiment triplicate, the IC of drug effect behind various cell 72h 50 Value sees Table 6. The IC of table 6 drug effect behind various cell 72h 50 (ugmL -1 ) Claims ( 8 ) Translated from Chinese 1.一种提取纯化马钱子总生物碱的方法，其特征在于步骤如下： 1. A method for extracting and purifying total alkaloids of Nuxychnium chinensis, characterized in that the steps are as follows: (1)将马钱子药材，粉碎成粗粉，称取100-200克粗粉； (1) Pulverize the Nuxychnium medicinal material into coarse powder, and take 100-200 grams of coarse powder; (2)用1000-2000ml的乙醇回流提取，减压回收乙醇，得醇浸膏； (2) reflux extraction with 1000-2000ml of ethanol, reclaim ethanol under reduced pressure, and obtain alcoholic extract; (3)用400-1000ml的盐酸溶解上述醇浸膏，离心，取上清； (3) Dissolve the above-mentioned alcoholic extract with hydrochloric acid of 400-1000ml, centrifuge, and get the supernatant; (4)加入氢氧化钠，调节pH值为10-14，将该溶液用500-2000ml的二氯甲烷进行萃取，减压除去溶剂得马钱子总生物碱粉末； (4) Add sodium hydroxide to adjust the pH value to 10-14, extract the solution with 500-2000ml of dichloromethane, and remove the solvent under reduced pressure to obtain the total alkaloid powder of Nuxebra chinensis; (5)将上述马钱子总生物碱粉末，用1000-3000ml50-90％乙醇超声溶解； (5) Dissolve the above-mentioned total alkaloid powder of Nuxebra chinensis with 1000-3000ml50-90% ethanol ultrasonically; (6)减压浓缩至原体积的0.4-0.05倍，离心浓缩液，取上清液； (6) concentrating under reduced pressure to 0.4-0.05 times of the original volume, centrifuging the concentrate, and taking the supernatant; (7)将上清液冷藏静置，离心除去沉淀，然后上清液干燥得纯化马钱子总生物碱。 (7) The supernatant was refrigerated and left still, and the precipitate was removed by centrifugation, and then the supernatant was dried to obtain purified total alkaloids of St. Chin. 2.根据权利要求1所述的提取纯化马钱子总生物碱的方法，其特征在于步骤(2)中所述的乙醇浓度为50-95％，加热回流次数为1-5次，每次加热回流时间为0.5-2h。 2. the method for extracting and purifying the total alkaloids of Nuxebra chinensis according to claim 1 is characterized in that the ethanol concentration described in the step (2) is 50-95%, and the number of times of heating and refluxing is 1-5 times, each time Heating and reflux time is 0.5-2h. 3.根据权利要求1所述的提取纯化马钱子总生物碱的方法，其特征在于步骤(3)中所述的盐酸浓度为0.1-1mol/L。 3. the method for extracting and purifying the total alkaloids of Nuxebra chinensis according to claim 1, is characterized in that the hydrochloric acid concentration described in step (3) is 0.1-1mol/L. 4.根据权利要求2所述的提取纯化马钱子总生物碱的方法，其特征在于步骤(7)中所述的冷藏温度为0-10℃，所述的干燥方法为常压干燥或真空干燥。 4. the method for extracting and purifying total alkaloids of Nuxebra chinensis according to claim 2, is characterized in that the refrigerated temperature described in step (7) is 0-10 ℃, and described drying method is normal pressure drying or vacuum dry. 5.如权利要求1提取方法所得纯化马钱子总生物碱在制备镇痛药物中的应用。 5. The application of the purified Nuxychnium chinensis total alkaloids as claimed in claim 1 in the preparation of analgesic drugs. 6.如权利要求1提取方法所得纯化马钱子总生物碱在制备抗炎药物中的应用。 6. The application of the purified Nuxychnium chinensis total alkaloids as claimed in claim 1 in the preparation of anti-inflammatory drugs. 7.如权利要求1提取方法所得纯化马钱子总生物碱在制备抗肿瘤药物中的应用。 7. The application of the purified Nuxychnium chinensis total alkaloids as claimed in claim 1 in the preparation of antineoplastic medicaments. 8.如权利要求1提取方法所得纯化马钱子总生物碱在制备免疫调节药物中的应用。 8. The application of the purified Nuxychnium chinensis total alkaloids obtained by the extraction method according to claim 1 in the preparation of immunomodulatory drugs. CN2010101072954A 2010-02-08 2010-02-08 Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy Expired - Fee Related CN101804096B ( en ) Priority Applications (1) Application Number Priority Date Filing Date Title CN2010101072954A CN101804096B ( en ) 2010-02-08 2010-02-08 Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy Applications Claiming Priority (1) Application Number Priority Date Filing Date Title CN2010101072954A CN101804096B ( en ) 2010-02-08 2010-02-08 Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy Publications (2) Publication Number Publication Date CN101804096A true CN101804096A ( en ) 2010-08-18 CN101804096B CN101804096B ( en ) 2011-11-09 Family ID=42606156 Family Applications (1) Application Number Title Priority Date Filing Date CN2010101072954A Expired - Fee Related CN101804096B ( en ) 2010-02-08 2010-02-08 Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy Country Status (1) Country Link CN ( 1 ) CN101804096B ( en ) Cited By (7) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title CN103027946A ( en ) * 2011-09-30 2013-04-10 北京因科瑞斯医药科技有限公司 Method for extracting total alkaloids in semen strychni CN103159774A ( en ) * 2011-12-09 2013-06-19 北京因科瑞斯医药科技有限公司 Extraction, separation and purification method for strychnos total alkaloid CN103908493A ( en ) * 2014-03-20 2014-07-09 浙江工业大学 Preparation method and pharmaceutical application of nux vomica total alkaloids CN105384747A ( en ) * 2015-11-24 2016-03-09 正源堂（天津）生物科技有限公司 Brucine extraction method CN105524073A ( en ) * 2015-12-09 2016-04-27 正源堂（天津）生物科技有限公司 Method for extracting brucine N-oxide from nux vomica CN112641827A ( en ) * 2020-11-30 2021-04-13 山东中医药大学 Preparation method of compatible traditional Chinese medicine for preventing and treating arthralgia syndrome CN118086178A ( en ) * 2024-03-21 2024-05-28 重庆市铂而斐细胞生物技术有限公司 Cultivation and extraction method of small molecule metabolites of endothelial progenitor cells and their uses Family Cites Families (1) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title CN101496833B ( en ) * 2009-02-24 2011-09-14 湘潭大学 Liquid external preparation for preparing total alkaloids in nux vomica 2010 2010-02-08 CN CN2010101072954A patent/CN101804096B/en not_active Expired - Fee Related Cited By (9) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title CN103027946A ( en ) * 2011-09-30 2013-04-10 北京因科瑞斯医药科技有限公司 Method for extracting total alkaloids in semen strychni CN103027946B ( en ) * 2011-09-30 2015-05-13 北京因科瑞斯医药科技有限公司 Method for extracting total alkaloids in semen strychni CN103159774A ( en ) * 2011-12-09 2013-06-19 北京因科瑞斯医药科技有限公司 Extraction, separation and purification method for strychnos total alkaloid CN103159774B ( en ) * 2011-12-09 2015-07-08 北京因科瑞斯医药科技有限公司 Extraction, separation and purification method for strychnos total alkaloid CN103908493A ( en ) * 2014-03-20 2014-07-09 浙江工业大学 Preparation method and pharmaceutical application of nux vomica total alkaloids CN105384747A ( en ) * 2015-11-24 2016-03-09 正源堂（天津）生物科技有限公司 Brucine extraction method CN105524073A ( en ) * 2015-12-09 2016-04-27 正源堂（天津）生物科技有限公司 Method for extracting brucine N-oxide from nux vomica CN112641827A ( en ) * 2020-11-30 2021-04-13 山东中医药大学 Preparation method of compatible traditional Chinese medicine for preventing and treating arthralgia syndrome CN118086178A ( en ) * 2024-03-21 2024-05-28 重庆市铂而斐细胞生物技术有限公司 Cultivation and extraction method of small molecule metabolites of endothelial progenitor cells and their uses Also Published As Publication number Publication date CN101804096B ( en ) 2011-11-09 Similar Documents Publication Publication Date Title CN101804096A ( en ) 2010-08-18 Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy CN101747405A ( en ) 2010-06-23 Berberine glycyrrhizic acid enantiomer salt and preparation method and usage thereof CN103130865B ( en ) 2016-08-03 Matrine, oxymatrine enoxolone double salt and preparation method thereof, purposes CN112274541B ( en ) 2022-05-17 Application of semiliquidambar cathayensis aqueous extract in preparation of antitumor drugs CN101904974B ( en ) 2011-09-14 Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof WO2013155995A1 ( en ) 2013-10-24 Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor CN102309483B ( en ) 2013-01-02 New application of berberine ion pair compound in tumor resistance CN102786573A ( en ) 2012-11-21 Glycyrrhetinic acid crystal B substance, its preparation method, and its applications in medicines and healthcare products CN103585154B ( en ) 2015-04-22 New application of 8-methoxyl-dihydro chelerythrine for preparing drug for treating burn and scald inflammation CN101822705A ( en ) 2010-09-08 Total platycodin and application of monomer platycodin D in antialcoholic drugs CN112274542A ( en ) 2021-01-29 Application of semiliquidambar cathayensis or extract thereof in preparation of anti-depression drugs CN102302545A ( en ) 2012-01-04 Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application CN101569654A ( en ) 2009-11-04 Supercritical extract of pigeon pea leaves and application of pigeon pea stilbene acid in the preparation of antitumor drug CN106974981A ( en ) 2017-07-25 A kind of external used medicine of analgesic CN107213176B ( en ) 2020-07-28 A kind of hydrangea leaf extract and its pharmaceutical composition, preparation method and application CN106565849B ( en ) 2018-10-09 A kind of preparation method and applications of aizoon stonecrop polysaccharide CN105168300A ( en ) 2015-12-23 Pharmaceutical composition for treating diabetes and preparation method thereof CN101721437A ( en ) 2010-06-09 Medicine composition used for treating chronic pharyngitis and preparation method thereof CN101502536A ( en ) 2009-08-12 Cedar total flavone as well as preparation method and medical use CN103316120A ( en ) 2013-09-25 Applications of clausena excavata burm and extractive thereof CN102379889A ( en ) 2012-03-21 Application of atemisia gmelinii extract in preparing drugs for preventing liver injuries CN103393738B ( en ) 2015-07-22 Traditional Chinese medicine composition for preventing influenza A viruses H1N1 CN101574422A ( en ) 2009-11-11 Medicine composition and preparation method thereof CN102579517B ( en ) 2014-03-19 Medicament composition for preventing prostatic diseases CN106074719A ( en ) 2016-11-09 Plumula Nelumbinis extract is in the application of preparation treatment pulmonary fibrosis medicine Legal Events Date Code Title Description 2010-08-18 C06 Publication 2010-08-18 PB01 Publication 2010-10-06 C10 Entry into substantive examination 2010-10-06 SE01 Entry into force of request for substantive examination 2011-11-09 C14 Grant of patent or utility model 2011-11-09 GR01 Patent grant 2018-02-27 CF01 Termination of patent right due to non-payment of annual fee Granted publication date : 20111109 Termination date : 20170208 2018-02-27 CF01 Termination of patent right due to non-payment of annual fee</div>
    </div>
    <!-- Metadata for experiment tracking -->
    <div class="metadata" data-behavior="strychnine_plant_extraction_instructions" data-stance="1" data-type="explicit" data-dataset="validation"></div>
</body>
</html>
